Island Pharmaceuticals
Island Pharmaceuticals is focused on drug repurposing and clinical development for viral diseases lacking existing therapies. Their business model centers around identifying and developing solutions for unmet medical needs in the treatment of viral infections. The company aims to create value by advancing repurposed drug candidates through clinical trials and ultimately to market.
Short position
Island Pharmaceuticals (ASX:ILA) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in March 2023. ILA is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Island Pharmaceuticals (ILA) short interest history
ILA Short Interest History
- 30-day change
- 0.00pp
- 90-day change
- -0.00pp
- 1-year change
- +0.00pp
- All-time high
- 0.19% (March 2023)
- All-time low
- 0.00% (September 2025)
Is ILA heavily shorted?
Not especially: 0.00% short interest is modest by ASX standards, ranking #785 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has ILA's short interest changed recently?
Over the past 30 days Island Pharmaceuticals's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.00% of shares on issue.
What is the highest ILA's short interest has been?
Since 2021, Island Pharmaceuticals's short interest peaked at 0.19% in March 2023 and bottomed at 0.00% in September 2025.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2021. See our methodology.